Outlook Therapeutics ( NASDAQ: OTLK ) announced that UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for LYTENAVA for the treatment of wet AMD. This approval comes after Outlook Therapeutics was recently granted Marketing Authorization for LYTENAVA by the European Commission for the same therapeutic indication. Initial commercial launches of LYTENAVA in the EU and UK anticipated in calendar Q1 2025.
Source: Press Release More on Outlook Therapeutics Outlook Therapeutics: Worth A Good Strong Look After CRL Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript Outlook gets EU approval for Lytenava for wet AMD Seeking Alpha’s Quant Rating on Outlook Therapeutics.
